C3 rs2250656: Macular Degeneration Risk Explained
The single-nucleotide polymorphism rs2250656 is a genetic variation located within the complement component 3 (C3) gene. Scientific studies have identified moderate statistical associations between this variant and altered susceptibility to age-related macular degeneration, specifically the neovascular (wet) subtype. Carrying specific alleles does not cause vision loss on its own, but rather modifies lifetime statistical risk alongside other genetic loci and lifestyle factors.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| Homozygous Reference | Carries two copies of the primary reference allele. This genotype is associated with baseline population susceptibility to neovascular macular degeneration. It does not confer complete protection against vision disorders. | Informational |
| Heterozygous | Carries one reference allele and one variant allele at the rs2250656 locus. This genotype shows a modest statistical variation in susceptibility to complement-associated retinal phenotypes. Overall risk remains heavily influenced by other genetic variants and environmental factors. | Informational |
| Homozygous Alternate | Carries two copies of the alternate allele at rs2250656. In observational cohorts, this genotype has demonstrated a moderate statistical association with altered risk for advanced neovascular AMD. It serves as an informative risk marker rather than a diagnostic indicator. | Higher attention |
What is rs2250656 and Where is It Found?
The marker rs2250656 represents a single-nucleotide polymorphism (SNP) situated within the complement component 3 (C3) gene on chromosome 19. At this genomic position, individuals inherit either a common reference nucleotide or an alternate allele. In human genomics, variations in this region are categorized primarily under the trait and complex disease spectrum rather than single-gene mendelian disorders. Because rs2250656 is located within an established immune regulatory locus, it serves as an informative genetic tag for researchers mapping disease architecture across different populations. Genetic variation in this non-coding or coding segment may act in linkage disequilibrium with other functional variants nearby, altering the transcriptional regulation or protein stability of complement factors involved in inflammatory cascades.
The Biological Role of Complement Component 3
The C3 gene encodes complement component 3, a central protein in the human immune system's complement cascade. As a core component shared across the classical, lectin, and alternative pathways, C3 activation produces cleavage fragments such as C3a and C3b. These molecules mediate local inflammation, enhance the clearance of cellular debris, and recruit immune cells. In the eye, tight regulation of complement activation is essential for maintaining retinal tissue integrity and homeostasis in Bruch's membrane. When regulation falters, chronic local activation can trigger inflammatory damage and cellular stress. Over time, excessive complement activity promotes the accumulation of subretinal extracellular deposits, termed drusen, which represent hallmark pathological precursors to progressive retinal degeneration.
Association with Age-Related Macular Degeneration
Research published in genomic literature, such as meta-analyses indexed in PubMed and the GWAS Catalog, evaluates rs2250656 for its role in age-related macular degeneration (AMD). Neovascular, or wet, AMD occurs when abnormal, leaky blood vessels proliferate beneath the retina, causing rapid central vision impairment. While key missense variants in C3—such as rs2230199 (Arg80Gly)—demonstrate strong and reproducible odds ratios, rs2250656 exhibits moderate evidence strength. Some studies find modest associations with advanced choroidal neovascularization, while others note that the signal is partially driven by linkage disequilibrium with neighboring primary drivers. Consequently, rs2250656 is considered a contributing risk modifier rather than a primary causal determinant in retinal disease.
Population Distribution and Genetic Frequency
Global population genetic databases, including gnomAD and dbSNP, show that the minor allele at rs2250656 occurs at frequencies generally ranging between 0.15 and 0.25 across broad continental populations. However, allele distributions are not completely uniform worldwide. Cohort studies have predominantly evaluated C3 associations within populations of European ancestry, where complement-mediated risk architecture is well-characterized. In East Asian, African, and Middle Eastern populations, allele frequencies and linkage patterns can diverge, occasionally altering the predictive strength of the SNP. These ancestral differences underscore why findings from European cohorts cannot be uniformly extrapolated to all genetic backgrounds without careful ancestral context.
Understanding What Your Results Mean
Identifying your rs2250656 genotype provides probabilistic insight into genetic variation, not a clinical diagnosis or definitive prognosis. Complex diseases such as macular degeneration arise from an interplay among dozens of complement loci (including CFH and CFI), overall polygenic architecture, and environmental exposures. Modifiable lifestyle factors, particularly tobacco smoking, dietary intake of antioxidants, and cardiovascular health, exert profound effects on the likelihood of disease development and progression. Genetic data should be viewed as background context rather than fate. Individuals seeking to monitor their vision health should consult eye care professionals for routine retinal examinations, which remain the clinical standard for detecting early disease signs.
How common is this variant?
The minor allele frequency for rs2250656 typically ranges between 0.15 and 0.25 across global populations, though frequency variations exist across distinct ancestral backgrounds.
Frequently asked questions
Does having the rs2250656 risk allele mean I will go blind?
No. The presence of a risk allele only indicates a modest statistical variation in susceptibility to age-related macular degeneration. Most individuals who carry the variant never develop advanced retinal disease, because multiple genes and environmental factors determine clinical outcomes.
Can diet or lifestyle influence my risk if I have this variant?
Yes. Lifestyle factors such as smoking cessation, maintaining healthy blood pressure, and consuming a nutrient-dense diet rich in leafy greens and omega-3 fatty acids significantly influence eye health. These interventions remain effective regardless of your specific complement genotypes.
Is rs2250656 used to select AMD medications?
Currently, rs2250656 is not used to direct standard clinical drug dosing or treatment selection. While therapies targeting the complement system are emerging for macular conditions, any medical treatment or testing decisions must be made in consultation with an ophthalmologist or clinical specialist.
How is rs2250656 different from other C3 variants?
While rs2250656 is a common marker showing moderate statistical association, other variants like the C3 Arg80Gly polymorphism (rs2230199) have demonstrated stronger, direct functional impacts on complement activation in published studies. rs2250656 often functions as an accompanying marker in broader haplotype blocks.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2250656?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in C3
Complement component 3 variant demonstrating sex-divergent modulation of neovascular AMD susceptibility.
Complement component 3 locus variant identified in genetic association studies of age-related macular degeneration and complement activation.
This functional coding variant (Arg102Gly) in complement component 3 significantly elevates the risk of developing age-related macular degeneration.